Prognostic value of sTREM-1 in COVID-19 patients: a biomarker for disease severity and mortality

Pedro V. da Silva Neto[1,2*], Jonatan C. S. de Carvalho[1,3*], Vinícius E. Pimentel[1,4*], Malena M. Pérez[1*], Ingryd Carmona-Garcia[3,5*], Nicola T. Neto[5*], Diana M. Toro[1,2*], Camilla N. S. Oliveira[1,4*], Thais F. C. Fraga-Silva[4],Cristiane M. Milanezi[4], Lilian C. Rodrigues[1], Cassia F. S. L. Dias[1], Ana C. Xavier[5], Giovanna S. Porcel[5], Isabelle C. Guarneri[5], Kamila Zaparoli[5], Caroline T. Garbato[5], Jamille G. M. Argolo[5], Ângelo A. F. Júnior[5], Alessandro P. de Amorim[10], Augusto M. Degiovani[10], Dayane P. da Silva[10], Debora C. Nepomuceno[10], Rafael C. da Silva[10], Leticia F. Constant[10], Fátima M. Ostini[10]. Marley R. Feitosa[6], Rogerio S. Parra[6], Fernando C. Vilar[7], Gilberto G. Gaspar[7], José J. R. da Rocha[6], Omar Feres[6], Rita C. C. Barbieri[11], Fabiani G. Frantz[1], Sandra R. Maruyama[8], Elisa M. S. Russo[1], Angelina L. Viana[5], Ana P. M. Fernandes[5], Isabel K. F. M. Santos[4], Vânia L. D. Bonato[4], Marcelo Dias-Baruffi[1], Adriana Malheiro[2], Ruxana T. Sadikot[9], Cristina R. B. Cardoso[1#], Lúcia H. Faccioli[1#] and Carlos A. Sorgi[2,3#].

[1]Departamento de Análises Clínicas, Toxicológicas e Bromatológicas. Faculdade de Ciências Farmacêuticas de Ribeirão Preto – FCFRP. Universidade de São Paulo – USP, Ribeirão Preto, SP, Brazil.

[2]Programa de Pós-Graduação em Imunologia Básica e Aplicada – PPGIBA. Instituto de Ciências Biológicas, Universidade Federal do Amazonas - UFAM, Manaus, AM, Brazil.

[3]Departamento de Química. Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto – FFCLRP. Universidade de São Paulo - USP, Ribeirão Preto, SP, Brazil.

[4]Departamento de Bioquímica e Imunologia. Faculdade de Medicina de Ribeirão Preto - FMRP. Universidade de São Paulo – USP, Ribeirão Preto, SP, Brazil.

[5]Escola de Enfermagem de Ribeirão Preto – EERP. Universidade de São Paulo – USP, Ribeirão Preto, SP, Brazil.

[6]Departamento de Cirurgia e Anatomia, Faculdade de Medicina de Ribeirão Preto - FMRP, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.

[7]Departamento de Clínica Médica, Faculdade de Medicina de Ribeirão Preto - FMRP, Universidade de São Paulo (USP), Ribeirão Preto, SP, Brazil.

[8]Departamento de Genética e Evolução, Centro de Ciências Biológicas e da Saúde Universidade Federal de São Carlos - UFSCar, São Carlos, SP, Brazil.

[9]Department of Veterans Affairs, Division of Pulmonary and Critical Care Medicine, Emory University, Atlanta, USA.

[10]Hospital Santa Casa de Misericórdia de Ribeirão Preto, Ribeirão Preto, SP, Brazil.

[11]Hospital São Paulo, Ribeirão Preto, SP, Brazil.

* These authors contributed equally to this work

\# These authors contributed equally to this work

Corresponding:
Carlos Arterio Sorgi, Ph.D – Departamento de Química - FFCLRP – USP –
Av. Bandeirantes, n.3900 – Ribeirão Preto / SP – 14040-901 – Brazil – Phone: (16) 3315 9176 - E-mail: carlos.sorgi@usp.br

Abstract

Background: The uncontrolled inflammatory response plays a critical role in the novel coronavirus disease (COVID-19) and triggering receptor expressed on myeloid cells-1 (TREM-1) is thought to be intricate to inflammatory signal amplification. This study aims to investigate the association between soluble TREM-1 (sTREM-1) and COVID-19 as a prognostic biomarker to predict the disease severity, lethality and clinical management. **Methods:** We enrolled 91 patients with COVID-19 in domiciliary care (44 patients) or in hospital care (47 patients), who were classified after admission into mild, moderate, severe and critical groups according to their clinical scores. As non-COVID-19 control, 30 healthy volunteers were included. Data on demographic, comorbidities and baseline clinical characteristics were obtained from their medical and nurse records. Peripheral blood samples were collected at admission and after hospitalization outcome to assess cytokine profile and sTREM-1 level by specific immunoassays. **Results:** Within COVID-19 patients, the highest severity was associated with the most significant elevated plasma levels sTREM-1. Using receiver operating curve analysis (ROC), sTREM-1 was found to be predictive of disease severity (AUC= 0.988) and the best cut-off value for predicting in-hospital severity was $\geq$ 116.5 pg/mL with the sensitivity for 93.3% and specificity for 95.8%. We also described the clinical characteristics of these patients and explored the correlation with markers of the disease aggravation. The levels of sTREM-1 were positively correlated with IL-6, IL-10, blood neutrophils counts, and critical disease scoring (r= 0.68, $p<0.0001$). On the other hand, sTREM-1 level was significantly negative correlated with lymphocytes counting, and mild disease (r= -0.42, $p<0.0001$). Higher levels of sTREM-1 were related to poor outcome and death, patients who received dexamethasone tended to have lower sTREM-1 levels. **Conclusion:** Our results indicated that sTREM-1 in COVID-19 is associated with severe disease development and a prognostic marker for mortality. The use of severity biomarkers such as sTREM-1 together with patients clinical scores could improve the early recognition and monitoring of COVID-19 cases with higher risk of disease worsening. **Key words:** COVID-19; sTREM-1; Inflammation; Biomarker; Severity; Mortality.

Introduction

The new coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), it became a worldwide public health problem due to high rates of morbidity and mortality. Approximately 80% of patients infected with SARS-CoV-2 may have mild symptoms or are asymptomatic. However, the virus is capable of causing serious clinical manifestations, such as acute respiratory distress syndrome (ARDS), cardiovascular and coagulopathy disorders and shock; resulting in multi-organ system dysfunction in some patients (1–10). Patients with older ages, male gender, obesity, and chronic comorbidities such as cardiovascular disease, diabetes, chronic respiratory disease, and cancer were more likely to have worse outcomes (11–13). Moreover, patients with COVID-19 present multiple hematological abnormalities, of which lymphopenia and thrombocytopenia were prominent (14).

Similar to SARS, inflammation plays a major role in the pathophysiology of COVID-19 and patients exhibiting severe disease may have systemic high concentrations of inflammatory makers in serum samples, such as IL-6, TNF-α, C-reactive protein (CRP) and D-dimer (10,15–21). Pathogen infections generate an innate response that is initiated by the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs) followed an antigen-specific adaptive immune response. Both innate and adaptive immune responses induce the activation of cell receptors and soluble mediators that trigger inflammation and its balance is critical for controlling tissue damage (22). Significant evidence indicates that a dysregulated immune and inflammatory response contributes to the clinical presentation of patients with severe COVID-19 disease.

Triggering receptor expressed on myeloid cells 1 (TREM-1) is a member of the immunoglobulin superfamily expressed in myeloid and epithelial cells. TREM-1 activation induces secretion of TNF-α, IL-6, IL-1β, IL-2, IL-12p40 by monocytes, macrophages and dendritic cells, enhancing inflammation during infections by different pathogens, namely Influenza A virus, Dengue virus, Hepatitis C virus, *Plasmodium falciparum*, *Staphylococcus aureus* and *Pseudomonas aeruginosa* (23–29). Immune responses against to virus and bacterial are modulated by

activation of TREM-1 in macrophages. TREM-1 KO mice are protected from severe influenza although viral clearance is unaltered (30). Similarly, HIV infection, or even exposure to the HIV proteins, Tat or gp120, in the absence of infection (31) induce expression of TREM-1 suggesting that TREM-1 may have a pathogenic role in viral infections and immune response.

Soluble form of the TREM-1 (sTREM-1) has been reported in plasma samples during infection and inflammation (32–35). The sTREM-1 is a 27kDa polypeptide in wich the with the extracellular domain is released from the cell surface by action of metalloproteinases (36). Interestingly, the serum sTREM-1 level measurements could be a valuable diagnostic biomarker and may be useful in predicting severe prognosis in diseases related to inflammatory processes, as seen in septic patients, Hepatitis B virus, Human Immunodeficiency virus (HIV), Crimean Congo Hemorrhagic Fever and *Mycobacterium tuberculosis infections* (27,33,37–39).

Given that SARS-CoV-2 infection induces a hyper-inflammatory response, we hypothesized that TREM-1 activation in the COVID-19 illness triggers upregulation and shedding into sTREM-1. Because, sTREM-1 has been validated as prognostic markers in various inflammatory disorders, we performed herein a prospective study to investigate the prognostic utility of sTREM-1 in patients with COVID-19, as an important biomarker that can predicts disease severity and qualify effective interventions for managing patients that need intensive supportive care upon hospitalization.

MATERIAL AND METHODS

Study Design and subjects

This prospective study was conduced at *Hospital Santa Casa de Misericórdia of Ribeirão Preto* and *Hospital São Paulo of Ribeirão Preto - Brazil* from April to August of 2020 and was conducted with strict and reasonable inclusion and exclusion criteria. The patient inclusion criteria were adults (aged over 18 years), positive for SARS-CoV-2 infection that understood and agreed to enroll in this study. Controls (healthy adult volunteers) were tested negative for SARS-CoV-2. The exclusion criteria were individuals younger than 18 years of age and

pregnant or lactating women. In total, 30 control subjects were enrolled at the
beginning of the COVID-19 pandemic with a negative test for SARS-CoV-2 and
91 patients with a positive test for SARS-CoV-2, using genomic RNA assay
performed in a nasopharyngeal/oropharyngeal swab RT-PCR (Kit Biomol
OneStep/COVID-19) or serology specific IgM and IgG antibodies (SARS-CoV-2
antibody test[®], Guangzhou Wondfo Biotech, China).

Data collection

Members of our team carefully collected and reviewed the medical records of
each patient. The data were searched and compiled from the electronic medical
and nursering record systems. We included sociodemographic information,
comorbidities, medical history, clinical symptoms, routine laboratory tests,
immunological tests, chest computed tomography (CT) scans results, clinical
interventions, and outcomes. These informations were documented on a
standardized record form. Data collection of laboratory results was defined using
the first-time examination at admission (within 24 h after admission), defined as
primary endpoint, and the secondary endpoint was clinical outcome (death or
recovery).

Severity assessment

Clinically, severity of the COVID-19 patients was classified into mild, moderate,
severe, and critical ill according to the statement in the Novel Coronavirus
Pneumonia Diagnosis and Treatment Guideline (7th ed.), with modifications (40).
The clinical manifestations were categorized as: i) mild group - positive for SARS-
CoV-2 infection, with or without the following symptoms: diarrhea, cough, fever,
headache, loss of taste (ageusia)/ smell (anosmia), myalgia, nausea, and
vomiting, oxygen saturation between 94-99 % on room air; ii) moderate group -
patients having manifestation of mild disease, with symptoms including dyspnea,
oxygen saturation ≥ 93% on room air and arterial partial pressure of oxygen
(PaO_2)/ oxygen concentration (FiO_2) between 250-300 mmHg, do not need
invasive ventilation, allegedly using nasal-cannula oxygen (2-4 L/min) or oxygen
masks ventilation (4-12 L/min); iii) severe group - possible admission to intensive-

care units, severe respiratory distress, oxygen saturation < 93% on room air and
PaO_2/ FiO_2 < 250mmHg, need non-invasive ventilation, such as oxygen masks
ventilation (10-15 L/min); and iv) critical group - admission to intensive-care units,
acute respiratory distress syndrome, need invasive ventilation, PaO_2/ FiO_2
<200mmHg, with or without one or more additional parameters: need
hemodialysis, sepsis, septic shock, and multiorgan dysfunction (41).

Laboratory Methods

Blood samples were collected by venipuncture in tubes with vacuum collection
system. Two tubes (5mL capacity) were collected from each patient: one tube
containing EDTA anticoagulant (BD Vacutainer® EDTA K2 Franklin Lakes, New
Jersey, USA) to perform hematological tests, and a tube containing heparin
anticoagulant (BD SST® Gel Advance® Franklin Lakes, New Jersey, USA) to
obtain plasma used to quantify levels of circulating protein mediators by flow
cytometry or ELISA assay. Plasma was separated from whole blood samples and
stored in a -80°C freezer. The clinical laboratory investigation included a complete
blood count and biochemical serum tests (including liver and kidney function), as
well as the determination of the coagulation factors and myocardial enzyme
spectrum.

Cytokines measurement

The cytokines IL-6 and IL-10 were quantified by the Cytometric Bead Array
technique, according to the manufacturer's specifications (BD™ Human
Inflammatory Cytokine CBA Kit, Catalog No. 551811, Lot: 9341655). Briefly, 50µl
of plasma samples were mixed with capture antibody-coupled beads, and then
50µl fluorescent labeled (PE) detection antibodies. The samples were mixed and
incubated at room temperature in the dark. After 3 h incubation, the beads were
washed and resuspended with PBS 1% paraformaldehyde (*v/m* – Sigma
Chemical Co. St. Louis, MO – USA). A recombinant protein standard for each
cytokine that provides an internal control was included. The detection range of
each cytokine was 2.5 pg/ml to 5000 pg/ml. Data acquisition was performed using
a FACSCanto II flow cytometer (FACS CantoTMII – BD Biosciences, San Diego,

CA, USA). Data was analyzed using FCAP Array 3.0 software and expressed as
mean fluorescence intensity (MIF) for each serum cytokine (BD Biosciences, San
Diego, CA, USA).

Serum sTREM-1 assay

205 Circulating level of sTREM-1 were measured in plasma by an established
206 available enzyme linked immunosorbent assay kit (DuoSet- Human TREM-1,
207 R&D System, Minneapolis, USA), with a detection range of 93.8 – 6,000 pg/mL.
208 The methodology was in according to the protocol described by the manufacturer
209 (R&D Systems, Minneapolis, MN).

Computation of Correlation Matrix

The dependence of multiple variables: sTREM-1 release (pg/mL); oxygen
saturation (sO_2 %); age (years); neutrophil count (x 10^9 cells/L); lymphocytes
count (x 10^9 cells/L); hypertension (systole); glycemia (mg/dL); male gender;
clinical scores (mild, moderate, severe and critical); IL-6 (pg/mL) and IL-10
amount (pg/mL); was calculated using Pearson correlation with cor() function in
R (version 4.0.2) through RStudio (version 1.1.463). The computed correlation
matrix was graphically displayed using corrplot function from R package "corrplot"
(Version 0.84) (42). Correlation coefficients (r) and *p*-values of the correlation
matrix were formatted and tabulated using Hmisc R package (43) and the values
available at Supplemental Table S2.

Statistical analysis

Data is presented as either counts or percentages (%) (for categorical) or median
(IQR) and standard deviations (SD) for continuous data. Intergroup comparisons
were made by the Mann-Whitney *U* test (non-normally distributed continuous
variables) and chi-square test or Fischer's exact test for categorical variables.
One- way analysis of variance nonparametric test (Kruskal–Wallis test) was used
for multiple comparisons. The accuracy of predictor was determined by area
under the receiver operating characteristic (ROC) curve (AUC). The AUCs, with
95% confidence intervals, were computed to assess the diagnostic values of

sTREM-1; AUCs > 0.70 were considered clinically relevant. Comparative analysis
between groups was performed using GraphPad Prism™ software (version 8.4.2)
(San Diego, CA, USA). Statistical test differences were considered significant if
the p values were < 0.05.

Ethical approval

The procedures followed in this study were approved by the institutional ethics
board of *Faculdade de Ciências Farmacêuticas de Ribeirão Preto – Universidade*
de São Paulo and Brazil National Ethics Committee (CONEP, CAAE:
30525920.7.000.5403). Written informed consent was obtained from recruited
participants of the study.

RESULTS

Demographic data, initial clinical signs and laboratory characteristics of study
subjects

In total, 91 patients with laboratory-confirmed COVID-19 and 30 healthy
volunteers were recruited to the study (Table 1). In this study population, 44
patients were diagnosed with mild disease with residential care and 47 patients
with severe disease with hospital care on admission. The median age was 32.0
years (range, 23–80) for healthy volunteers and 49.0 years (range, 18–94) for all
patients infected with SARS-CoV-2. The average age was significantly higher in
the hospitalized patients than in residential care patients (Table 1). There was
significant difference in the female ratio between the healthy control group and
hospitalized COVID-19 patients (Table 1). Most patients had comorbidities or
coexisting disorders, including hypertension (29.6%), heart disease (10.9%),
diabetes (18.6%), neurological disorders (6.5%), cancer (5.4%), history of
smoking (19.7%), and history of stroke (3.2%). The number of comorbidities was
significantly higher in COVID-19 patients than in control group or in hospitalized
patients compared to residential care subjects (Table 1).

Generally, the most common initial symptoms in COVID-19 patients were
cough (62.6%), dyspnea (47.2%) and dysgeusia (35.1%), followed by diarrhea,
fever, muscle soreness, and hyperactive delirium (Table 1). In addition, the
absolute number of erythrocytes, hemoglobin, neutrophils, lymphocytes and

monocytes in the COVID-19 patients group were significant different than that in the control group, while the glycemic level was significant difference between the residential care and hospital care groups (Figure 1). The median time of hospitalization for COVID-19 patients was 10 days and some patients needed intensive care (42.5%). Also, those hospitalized patients received respiratory support: nasal-cannula oxygen (48.9%), oxygen masks ventilation (27,6%) and invasive mechanical ventilation (23.4%). The oxygen saturation was significantly lower in the hospitalized patients than in residential care patients (Table 1). The most common pharmacological treatments for COVID-19 patients were azithromycin (56.0%), dexamethasone (45.0%), ceftriaxone (41.7%), oseltamivir (37.3%), followed by cloroquine/hydroxycloroquine, ivermectin and anticoagulant.

Table 1. Demographics and clinical characteristics of patients infected with SARS-CoV-2.

Baseline Variable	Healthy Controls N= 30	All patients N= 91	COVID-19 care		P Value
			Residential N=44	Hospital N=47	
Demographic characteristics					
Age median ± SD, (IQR)	32.0 ± 14.1 (23-80)	49.0 ± 19.7 (18-94)	37.0 ± 10.7 (18-59)	66.0 ± 16.0 (30-94)	[a]**0.0002** [b,c]**< 0.0001**
Gender, No. (%)					
Male	17 (56.6)	46 (50.2)	15 (34.0)	31 (65.9)	[a]0.6744
Female	13 (43.3)	45 (49.4)	29 (65.9)	16 (34.0)	[c]**0.0033**
Comorbidities or coexisting disorders, No. (%)					
Hypertension	4 (13.3)	27 (29.6)	2 (4.5)	25 (53.1)	[a]0.0934 [c]**< 0.0001**
Cardiovascular disease	3 (10.0)	10 (10.9)	5 (11.3)	5 (10.6)	[a]1.0000 [c]1.0000
Diabetes *mellitus*	1 (3.3)	17 (18.6)	4 (9.0)	13 (27.6)	[a]**0.0419** [c]**0.0311**
History of smoking	7 (23.3)	18 (19.7)	4 (9.0)	14 (29.7)	[a]0.7952 [c]**0.0175**
History of stroke	-	3 (3.2)	-	3 (6.3)	-
Neurological	-	6 (6.5)	2 (4.5)	4 (4.8)	[c]0.6778
Cancer	-	5 (5.4)	-	5 (10.6)	-
Presenting symptoms, No. (%)					
Dyspnea	-	43 (47.2)	16 (36.3)	27 (57.4)	[c]0.1983
Fever	-	18 (19.7)	1 (2.2)	17 (36.1)	[c]**< 0.0001**
Myalgia	-	11 (12.0)	-	11 (23.4)	-
Diarrehea	-	28 (30.7)	18 (40.9)	10 (21.2)	[c]0.0681
Cough	-	57 (62.6)	32 (72.7)	25 (53.1)	[c]0.0822
Hyperactive Delirium	-	3 (3.2)	-	3 (6.3)	-
Dysgeusia	-	32 (35.1)	28 (63.6)	4 (8.5)	[c]**< 0.0001**
Laboratory findings, median ± SD, (IQR)					
Erythrocytes x 10^{12}/L	5.0 ± 0.5 (4.00-5.90)	4.5 ± 0.8 (2.23-5.89)	4.8 ± 0.4 (3.77-5.89)	3.9 ± 0.8 (2.23-5.67)	[a] **0.0011** [b] **< 0.0001**

Hemoglobin (g/dL)	15.1 ± 1.5 (11.30-17.50)	13.7 ± 2.6 (6.60-18.20)	14.6 ± 1.2 (12.70-18.20)	11.8 ± 2.6 (6.60-16.20)	[a]0.0006 [b]< 0.0001
Leukocytes x 10^9/L	7.6 ± 2.1 (4.10-13.44)	8.1 ± 4.5 (1.60-26.10)	7.7 ± 2.4 (3.24-13.58)	9.0 ± 5.6 (1.60-26.10)	[a]0.5548 [b]0.1342
Neutrophils x 10^9/L	57.4 ± 8.3 (36.00-74.60)	68.1 ± 16.0 (32.30-93.00)	57.2 ± 10.3 (32.30-77.80)	82.0 ± 8.2 (56.10-93.00)	[a]0.0001 [b]< 0.0001
Lymphocytes x 10^9/L	32.1 ± 8.3 (11.80-48.40)	20.5 ± 14.2 (1.00-58.00)	33.1 ± 9.3 (18.10-58.00)	9.7 ± 6.2 (1.00-31.80)	[a]0.0004 [b]< 0.0001
Monocytes x 10^9/L	7.2 ± 2.0 (3.80-13.00)	6.1 ± 2.9 (0.0-12.90)	7.0 ± 1.9 (3.20-11.20)	5.0 ± 3.3 (0.0-12.90)	[a]0.0054 [b]0.0001
Platelets x 10^9/L	219.5 ± 39.67 (129.0-297.0)	222.0 ± 96.2 (9.10-620.0)	231.9 ± 61.0 (119.0-365.0)	242.6 ± 121.7 (9.10-620.0)	[a]0.6639 [b]0.8674
Glycemia (mg/dL)	94.5 ± 43.74 (76.00-244.0)	99.0 ± 80.8 (9.0-479.0)	89.0 ± 69.1 (65.00-479.0)	115.5 ± 89.0 (9.0-467.0)	[a]0.9968 [c]0.0035
Hospital support, No. (%)					
Infirmary	-	27 (29.6)	-	27 (57.4)	-
Intensive care unit (ICU)	-	20 (21.9)	-	20 (42.5)	-
Hospitalization data, No.					
Hospitalization days, median(IQR)	-	10 (1-34)	-	10 (1-34)	-
Respiratory support received (%)					
Nasal-cannula oxygen	-	23 (25.2)	-	23 (48.9)	-
Oxygen masks/ Noninvasive	-	13 (14.2)	-	13 (27.6)	-
Invasive mechanical ventilation	-	11 (12.0)	-	11 (23.4)	-
Oxygen Saturation median ± SD (IQR)	97 ± 1.7 (92-99)	92 ± 9.2 (54-99)	97 ± 2.3 (90-99)	86 ± 11.0 (54-99)	[a]0.0015 [b,c]< 0.0001
Medications No. (%)					
Dexamethasone	-	41 (45.0)	5 (11.3)	36 (76.5)	[c]< 0.0001
Azithromycin	-	51 (56.0)	13 (29.5)	38 (80.8)	[c]< 0.0001
Ceftriaxone	-	38 (41.7)	-	38 (80.8)	-
Oseltamivir	-	34 (37.3)	5 (11.3)	29 (61.7)	[c]< 0.0001
Cloroquine/Hydroxycloroquine	-	12 (13.1)	-	12 (25.5)	-
Anticoagulant	-	3 (3.2)	-	3 (6.3)	-
Ivermectin	-	7 (7.6)	7 (15.9)	-	-

Abbreviation: SD: Standard deviation; Data are median (IQR), n (%), or n/N. [a]Comparing the healthy controls group with all patients; [b]Comparing the healthy controls group with residential and hospital COVID-19 patients, [c]Comparing the residential group with hospitalized subjects. Patients' data were compared using χ^2 test, or Fisher's exact test for categorical variables and one-way analysis of variance (ANOVA) Mann-Whitney, nonparametric *t*-test application was used for continuous variables. $p < 0.05$ was considered statistically significant.

sTREM-1 release is significantly associated with disease severity

The potential role of sTREM-1 in regulating infectious diseases has been extensively investigated elsewhere. Here, we compared the levels of sTREM-1 in plasma samples from control group and COVID-19 patients, and also, assessed the correlation with severity illness. As shown in Figure 1A, sTREM-1 values were higher in patients with COVID-19 and significantly different in hospitalized group when compared with healthy volunteer controls, indicating an activation of immune response against SARS-CoV-2 infection. To evaluate the prognostic value of sTREM-1 in patients with COVID-19, ROC curves were drawn for patients with COVID-19 in residential and hospital care versus healthy controls.

The area under ROC curve of sTREM-1 for residential care patients, which represent mostly the mild disease, was proximal to the considered value for clinical relevance (AUC= 0.691); the preoperative concentration of ≥ 69.5 pg/mL was the optimal cutoff value for predicting COVID-19 (sensitivity = 71.43 (54.9–83.6)%, specificity = 54.1%); the positive predictive values (PPV) of 91.6 (60.2–98.7)% and the negative predictive values (NPV) of 48.9 (43.0–54.9)% were described (Figure 1B). However, the area under ROC curve of sTREM-1 for hospital care patients, which denote the severe disease, was higher for clinical relevance (AUC= 0.988); the sTREM-1 cut-off value of ≥ 116.5 pg/mL yielded sensitivity of 93.3 (82.1–97.7)%, specificity of 95.83%, the PPV of 97.5 (85.4–99.6)%, and the NPV of 82.1 (66.7–91.4)% for differentiating patients with COVID-19 from those healthy subjects (Figure 1B). The plotted relative frequency of patients to sTREM-1 production, showed a high number of events for low level of sTREM-1 in residential care patients (mean = 113.68 pg/mL), and a spreader number of events for high levels of sTREM-1 in hospital care patients (mean = 325.18 pg/mL), considering a intersection phase between residential and hospitalized patients with COVID-19 (Figure 1C). Those results indicated the sTREM-1 as a potential marker predictive of COVID-19 severity illness.

Figure 1. The values of sTREM-1 in COVID-19 patients are elevated. (A) The plasma concentration of sTREM-1 from COVID-19 patients with residential (n=44); or hospital care (n=47); and healthy controls (n=30) were analyzed and compared with each other. Median with range was presented. One-way analysis of variance nonparametric test (Kruskal–Wallis test) was used for multiple comparisons when data were not normally distributed. The differences between each group were presented with a *p* value in the graphic above the diagram. **(B)** ROC curves sTREM-1 for predicting disease on residential care (blue) and hospital care (red) patients with COVID-19. The area under the curve (AUC) and the comparative *p* value between COVID-19 patients and control group was designated in the graphic. **(C)** Relative frequency of residential care (blue) and hospital care (red) on sTREM-1 release in COVID-19 patients. The mean, standard deviation, CL lower 95% and CL upper 95% data of each group were presented in the table under the diagram.

Correlation of sTREM-1 with disease severity, comorbidities and inflammatory mediators in COVID-19 patients

Subgroup analysis correlation of sTREM-1 in adverse outcome prediction was performed for patients according to different disease severity on admission. In this case, oxygen saturation (sO2), age, neutrophil count, lymphocytes count, hypertension, glycemia, male gender, clinical scores, IL-6 and IL-10 were identified as independent risk factors of adverse outcome in patients with COVID-19. For this, we performed analyses using the level of sTREM-1 in 91 patients'

plasma obtained during the period of SARS-CoV-2 infection diagnostic confirmation. In figure 2A, a correlation plot using correlation matrix (*r* values) showed statistically positively association of sTREM-1 level with critical disease, neutrophils count, age, and IL-10, IL-6 production. Conversely, we also observed a statistically negative association of sTREM-1 with mild disease and lymphocytes count. Full *r* and *p*-values of the correlation matrix are available in Supplemental Table S2. To further examine if higher sTREM-1 contributes to disease severity, we next analyzed sTREM-1 level in COVID-19 patients subgroups based on disease severity (Figure 2B). Despite significant differences between critical and severe or moderate and to mild groups, such significance was not seen for comparison between moderate and mild patients.

As expected, in figure 2C we demonstrated a positive correlation between sTREM-1 and neutrophils count, IL-10 and IL-6 levels. However, when comparing these independent risk factors with the adverse outcome in patients with COVID-19, we observed a homogeneity values for mild and moderate disease (Gate 1), and variable increased levels for severe (Gate 2) and critical disease (Gate 3). On this way, we suggested that sTREM-1 value is a better predictor of clinical outcome of the disease than other risk factors or inflammatory mediators. In addition, sTREM-1 negatively correlated with lymphocyte count; and as assumed, sTREM-1 levels improved the discrimination between the mild/moderate to severe and critical group when compared to total lymphocytes number. Interesting, we observed that the glycemia index was higher in severe group than in mild/moderate and critical group, indicating that a single analysis of glycemia cannot be used to classify adequatelly all the COVID-19 severity ranges.

Figure 2. Clinical and immunological parameters strictly correlated with sTREM-1 levels in COVID-19 patients. (A) Correlogram of sTREM-1 and cytokine levels in the plasma of COVID-19 patients with comorbidities and clinical characteristics. Color scale sidebar indicates the correlation coefficients (r), where blue means positive correlation and red means negative correlation. Square size and color intensity are proportional to the correlation coefficients. Statistically significant correlations of pairwise variable comparisons are indicated by *$p<0.05$, **$p<0.01$ and ***$p<0.001$. **(B)** The level of sTREM-1 in COVID-19 patients with different severity: mild (n= 23), moderate (n= 21), severe (n= 28) and critical (n= 19) group. Median with ranges

was presented. One- way analysis of variance nonparametric test (Kruskal–Wallis test) was used for multiple comparisons when data were not normally distributed. The differences between each group were presented with a *p* value in the graphic above the diagram. **(C)** The correlation of plasma sTREM-1 and lymphocytes count, glycemia, neutrophils count, IL-10 and IL-6 amount in patients with COVID-19 was represented by a dot-plot graphic. The lines indicated the median value of different variables of all patients. Gates are placed around populations with common characteristics of patients with COVID-19.

Added Prognostic Value of sTREM-1 to predict mortality risk in COVID-19

To perform longitudinal analysis, sTREM-1 in patients with COVID-19 was further monitored during hospitalization. To better view the overall changes of sTREM-1 level, the plasma concentrations in the admission (baseline level) and after in the outcome treatment (death or recovery) were compared (Figure 3A). Of note, mostly patients treated with dexamethasone showed a reduced or stabilized sTREM-1 release after treatment, with only two-outcome recovery patient. In contrast, plasma sTREM-1 was significantly elevated in patients with COVID-19 who were not treated with dexamethasone. Notably, no recovery outcome was observed in these subjects and thus this analysis showed that sTREM-1 was a significant predictor of mortality.

In figure 3B, we showed our cohort of COVID-19 hospital pharmacological therapies. Although there are no approved treatments for COVID-19, the hospital protocols issued for antibiotics, antivirals and anti-inflammatory drugs. While treatment in this study was not stratified by severity of disease, 14 hospitalized patients in this cohort longitudinal analysis have been treated with dexamethasone (73.68%); 14 patients with antibiotics (azithromycin/ceftriaxone 73.68%), 12 patients with oseltamivir (63.15%), 5 patients with hydroxicloroquine/cloroquine (26.3%) and 1 patient treated with anticoagulant (5,2%). The combined pharmacology approach for these patients with COVID-19 was represented by a Venn diagram (Figure 3B). Changes in oxygen support level from hospital admission to recovery or death were showed in Figure 3C. In our cohort, 9 patients were in hospital infirmary care (47.3%) and 10 patients were in intensive care unit (52.63%). Among those patients, 6 were on invasive mechanical ventilation (31.5%), 8 on oxygen masks non-invasive ventilation (42.1%) and 5 on oxygen nasal-cannula (26.3%) during hospitalization. The

398 details of hospital support and supportive therapies for patients with COVID-19
399 were demonstrated in Supplemental Table 1.

Figure 3. The kinetics of sTREM-1 in COVID-19 patients during hospitalization. (A) The plasma
sTREM-1 level of critical patients during hospitalization was presented. The graphics indicated the
individually value of sTREM-1 in the day of hospital-admission and after in the disease outcome, that can
be death (+) or recovery (-). The individuals were segmented according with pharmacology treatment in
dexamethasone-treatment and non-treatment with dexamethasone. Each circle indicates an individual
patient. Nonparametric *t* test (Mann-Whitney U test) was used to data not normally distributed. The
differences between the groups were presented with a *p* value in the graphics. **(B)** Venn diagram showed
all pharmacological treatment relations between dexamethasone, Oseltamivir, Piperacillin+Tazobactam,
Hydroxycloroquine/cloroquine, Azitromycin/Ceftriaxone of different sets patients with COVID-19 in hospital
care. **(C)** Demonstrative percentages of patients in distinctive hospital and respiratory support during
hospitalization.

DISCUSSION

To date, the most significant predictors of COVID-19 disease severity are relate to either activation or suppression of the host immune response (44,45). In the present study, we show for the first time in a population of patients in the city of Ribeirão Preto - Brazil with COVID-19 that plasma sTREM-1 concentrations might be a predictive factor and a biomarker for disease severity. Plasma sTREM-1 concentrations were gradually increased from mild to moderate, severe and critical forms of COVID-19. Indeed, ROC analysis confirms that sTREM-1 was an important predictor of disease progression in COVID-19 patients.

TREM-1 exhibit the ability to amplify proinflammatory innate immune response, such as by the Toll like receptors (TLR), which recognize a wide range of bacterial, fungal and viral components (46). In addition to neutrophils, monocytes and macrophages, TREM-1 is also expressed in epithelial and endothelial cells (25). Elevated sTREM-1 level are indicative of acute and chronic conditions including sepsis and pneumonia (47,48). Enhanced inflammatory response in macrophages was indicated as a mechanism by which TREM-1 signaling contributes to lung injury, suggesting that TREM-1 inhibition was a potential therapeutic target for neutrophilic lung inflammation and acute respiratory distress syndrome (ARDS) (49). Moreover, sTREM-1 level in sepsis could reflect an essential immune dysfunction, where excessive cleavage of TREM-1 could contribute to immunosuppression and death during a severe infection (50). Since severe infections can occur by multiple microorganism the broad prognostic of sTREM-1 implied its potential as a severity marker for all-cause febrile illness (51). However, fever was not the mostly common signs in admission patient with COVID-19 in our cohort, especially in mild and moderate disease. Thus, sTREM-1 has been recognized to be a valuable diagnostic and prognostic marker since it is easily detected using immunochemical assays. Nevertheless, the role of sTREM-1 in patients with COVID-19 remains unclear.

The number of COVID-19 patients is increasing dramatically worldwide and the early recognition of severe forms of COVID-19 is essential for timely triaging of patients. Some model analysis showed that IL-6 and CRP could be used as independent factors to predict the severity of COVID-19 (52). IL-6 is a

multifunctional cytokine that presented a strong proinflammatory effect with functions in inflammation, tumor, and hematological diseases (53,54). Other work suggested that the predictive values of IL-10 and IL-6 should be preferentially evaluated for early diagnosis of patients with severe disease (18). IL-10 is highly abundant, especially during the adaptive immune response (55). Although, some studies pointed that plasma IL-6 and IL-10 levels could be used as a factor to predict the progression of COVID-19, in our cohort these values alone did not distinguish the severe and critical groups, but these cytokines were in lower levels in mild/moderate disease and higher expression was observed in some patients with severe/critical COVID-19. Patients with severe COVID-19 disease presented with increased leukocytosis, neutrophilia, lymphopenia, and thrombocytopenia than those with non-severe disease (56); and we also demonstrated a significant correlation between plasma sTREM-1 and those hematological parameters in severe COVID-19.

Instead, sTREM-1 levels were found to be independent discriminators of disease severity on admission, we also comprised that sTREM-1 could be an outcome predictor for patients with COVID-19. Therefore, markedly elevated plasma sTREM-1 levels in patients with COVID-19 might be the indication of excessive inflammatory response and contribute to severe/critical illness or even death. Generally, the most common therapeutic options for viral infections are directed at either blocking viral replication or modulation of immune response. Dexamethasone exhibits broad-spectrum anti-inflammatory effects. In patients hospitalized with COVID-19, the use of dexamethasone resulted in lower mortality (57). We observed a longitudinal sTREM-1detection in patient admission and outcome in hospital care; in patients with non-treatment with dexamethasone, sTREM-1 increased after admission and correlated with outcome death. However, patients that were treated with dexamethasone, in mostly the case, control and reduced the sTREM-1 production, but this phenomenon was not correlated with better recovery. It means a non-return point to anti-inflammatory treatment in COVID-19, and sTREM-1 value could expose that inflammatory status. It is likely that the beneficial effect of glucocorticoids in severe COVID-19 is subject on a selection of dose and time.

There are some limitations in our study. First, chronic diseases and secondary infection in some cases might exert effects on the increased plasma sTREM-1 level besides SARS-CoV-2 infection itself. Second, this study was limited by sample size. Larger studies with continuous monitoring of sTREM-1 are necessary to further confirm the prognostic effect in patients with severe COVID-19. Exacerbation of the situation is usually a dynamic process; thus the data at a certain time point may not accurately reflect change in the patient condition. Third, some patients with critical illness were not admitted to intensive care unit, which definitely had a negative impact on the outcome of those patients. Although our findings should be evaluated with larger number of samples by multi-center research, sTREM-1 is a potential marker of diagnostic to distinguish critical COVID-19 and poor-outcome, and monitoring the sTREM-1 levels will improve treatment efficacy and reduce mortality.

CONCLUSION

In conclusion, our results suggested that admission plasma sTREM-1 levels play an important role in discriminating disease severity and predicting adverse outcome in patients with COVID-19. Patients with markedly elevated admission sTREM-1 should be provided more attention and supported treatment. In this perspective, we suggested the sTREM-1 value contribution to the clinical course of COVID-19 infection and highlight potential strategies for therapeutic intervention. Also, emerged as a possible prognostic biomarker readily detected in plasma of COVID- 19 patients.

ACKNOWLEDGEMENTS

The authors acknowledge the support of the ICU team of doctors, nurses, physiotherapists and the collaboration of *Hospital Santa Casa de Misericórdia of Ribeirão Preto* and *Hospital São Paulo of Ribeirão Preto.* The laboratory support from Supera Parque - Innovation and Technology Park- Ribeirão Preto/SP for testing infection by SARS-CoV-2 in healthy volunteers. The valuable contribution by Municipal Health Department of Ribeirão Preto city and Analysis Service Clinics (SAC) from Faculdade de Ciências Farmacêuticas de Ribeirão Preto – USP. We are grateful to Fabiana R. de Moraes for helping with Flow Cytometer

507 analysis; and Professors Victor Hugo Aquino Quintana and Márcia Regina von
508 Zeska Kress for sharing viral BSL2 lab.

509 **Supplementary Data**

510 **Supplemental Table 1. Hospital support, supportive therapies and**
511 **medications of patients severe and critical infected with SARS-CoV-2.**

During hospital stay	Severe/critical N=19
Hospital support, No. (%)	
Infirmary	9 (47.36)
Intensive care unit (ICU)	10 (52.63)
Hospitalization data, No.	
Hospitalization days, median (IQR)	10 (8-22)
Number of days since symptom onset (IQR)	6 (2-15)
Respiratory support received (%)	
Nasal-cannula oxygen	5 (26.31)
Non-rebreathing mask / Noninvasive ventilation	8 (42.10)
Invasive mechanical ventilation	6 (31.57)
Oxygen Saturation median (IQR)	93 (70-99)
Medications	
Dexamethasone	14 (73.68)
Azithromycin	14 (73.68)
Ceftriaxone	13 (68.42)
Oseltamivir	12 (63.15)
Cloroquine/Hydroxycloroquine	5 (26.31)
Anticoagulant	1 (5.26)
Death	17 (89.4)

513 Abbreviation: IQR, interquartile range, Data are median (IQR), n (%), or n/N.

514 **Supplemental Table 2. Information about r and *p*-values of the correlation**
515 **matrix of the graph shown in figure 2.**

Comparison	Row	Column	Correlation	p-value
1	sTREM1	Lymphocytes	-0,52170	1,14E-06
2	sTREM1	Neutrophils	0,58800	1,88E-08
3	Lymphocytes	Neutrophils	-0,44264	5,55E-05
4	sTREM1	Glycemia	0,09286	0,42182
5	Lymphocytes	Glycemia	-0,36861	0,00097
6	Neutrophils	Glycemia	0,09778	0,39753
7	sTREM1	IL10	0,42499	0,00012
8	Lymphocytes	IL10	-0,26048	0,02214
9	Neutrophils	IL10	0,27028	0,01744
10	Glycemia	IL10	0,12544	0,27703
11	sTREM1	IL6	0,43267	8,50E-05

12	Lymphocytes	IL6	-0,16860	0,14271
13	Neutrophils	IL6	0,35654	0,00146
14	Glycemia	IL6	-0,04650	0,68803
15	IL10	IL6	0,27826	0,01427
16	sTREM1	Mild	-0,42227	0,00011
17	Lymphocytes	Mild	0,64575	2,28E-10
18	Neutrophils	Mild	-0,34410	0,00218
19	Glycemia	Mild	-0,26277	0,02095
20	IL10	Mild	-0,17832	0,12075
21	IL6	Mild	-0,14227	0,21709
22	sTREM1	Moderate	-0,26402	0,01871
23	Lymphocytes	Moderate	0,25992	0,02244
24	Neutrophils	Moderate	-0,33536	0,00287
25	Glycemia	Moderate	-0,23557	0,03917
26	IL10	Moderate	-0,17433	0,12942
27	IL6	Moderate	-0,14347	0,21321
28	Mild	Moderate	-0,28445	0,01107
29	sTREM1	Severe	-0,04560	0,69176
30	Lymphocytes	Severe	-0,40727	0,00026
31	Neutrophils	Severe	0,17927	0,12125
32	Glycemia	Severe	0,52996	8,52E-07
33	IL10	Severe	-0,02137	0,85461
34	IL6	Severe	-0,03733	0,74885
35	Mild	Severe	-0,35237	0,00156
36	Moderate	Severe	-0,36560	0,00100
37	sTREM1	Critical	0,68800	6,59E-12
38	Lymphocytes	Critical	-0,44213	8,02E-05
39	Neutrophils	Critical	0,45144	5,41E-05
40	Glycemia	Critical	-0,05256	0,65648
41	IL10	Critical	0,45644	4,36E-05
42	IL6	Critical	0,37704	0,00093
43	Mild	Critical	-0,27454	0,01639
44	Moderate	Critical	-0,28493	0,01261
45	Severe	Critical	-0,33736	0,00288
46	sTREM1	Male	0,19819	0,08197
47	Lymphocytes	Male	-0,39743	0,00038
48	Neutrophils	Male	0,15473	0,18202
49	Glycemia	Male	0,28389	0,01295
50	IL10	Male	0,15893	0,17027
51	IL6	Male	-0,02913	0,80277
52	Mild	Male	-0,21052	0,06431
53	Moderate	Male	-0,17884	0,11721
54	Severe	Male	0,17882	0,11725

55	Critical	Male	0,20958	0,06921
56	sTREM1	Age	0,43058	8,32E-05
57	Lymphocytes	Age	-0,64649	2,83E-10
58	Neutrophils	Age	0,43821	7,52E-05
59	Glycemia	Age	0,33385	0,00321
60	IL10	Age	0,33105	0,00349
61	IL6	Age	0,27897	0,01467
62	Mild	Age	-0,50132	2,94E-06
63	Moderate	Age	-0,32776	0,00340
64	Severe	Age	0,41118	0,00020
65	Critical	Age	0,39176	0,00051
66	Male	Age	0,33291	0,00309
67	sTREM1	Systole	0,12566	0,27942
68	Lymphocytes	Systole	-0,10523	0,37222
69	Neutrophils	Systole	-0,03093	0,79362
70	Glycemia	Systole	0,12893	0,27360
71	IL10	Systole	-0,11298	0,33785
72	IL6	Systole	-0,05190	0,66054
73	Mild	Systole	-0,03689	0,75175
74	Moderate	Systole	-0,05579	0,63217
75	Severe	Systole	-0,04354	0,70879
76	Critical	Systole	0,11156	0,34401
77	Male	Systole	-0,02091	0,85768
78	Age	Systole	0,02243	0,84853
79	sTREM1	SaO$_2$	0,02523	0,82987
80	Lymphocytes	SaO$_2$	0,25259	0,02991
81	Neutrophils	SaO$_2$	-0,07563	0,52189
82	Glycemia	SaO$_2$	-0,03030	0,79774
83	IL10	SaO$_2$	-0,02714	0,81847
84	IL6	SaO$_2$	0,03383	0,77480
85	Mild	SaO$_2$	0,17241	0,13911
86	Moderate	SaO$_2$	0,12471	0,28640
87	Severe	SaO$_2$	-0,07139	0,54555
88	Critical	SaO$_2$	-0,24686	0,03658
89	Male	SaO$_2$	-0,11772	0,31784
90	Age	SaO$_2$	-0,31813	0,00574
91	Systole	SaO$_2$	0,03868	0,74523

NOTES

Author Contributions.

PVSN, JCSC, CAS and conceptualization the study. PVSN, JCSC, VEP, NTN performed the main experimental procedure. MMP, supervised the collection of samples from patients. PVSN, JCSC, YCG, ACX, GSP, ICG, KZ, CT G, JGMA, AAFJ, help with samples collection. PVSN, JCSC, TFCFS, CMM, LCR, CFSLD, sample processed and fractionation. CNSO, YCG, TFCFS, CRBC, performed the main experimental cytokines measurement. SRM, analyzed the data by R program. PVSN, DMT, CAS, performed the statistical analysis of the data and wrote the article and prepared the figures. DPS, DCN, RCS, LFC, RCCB, APA, AMD, FMO, MRF, RSP, FCV, GGG, JJRR, OF, contributed to the collection of clinical specimens, demographic, helped clinical data management and clinical characteristics analysis from COVID-19 patients. PVSN, DMT, CAS, drafted the manuscript. All authors helped editing the manuscript. CAS and LHF supervised the project. FGF, VLDB, CRBC and LHF, provided study materials, reagents and other analysis tools and equipment. CAS, FGF, SRCM, EMSR, ALV, APMF, IKFMS, VLDB, CRBC, MDB, AM, RTS, LHF, coordination and idealization of the project; and critical revision of the manuscript for important intellectual concept. All authors have read and agreed to the published version of the manuscript.

Financial support.

This work was supported by Fundação de Amparo a Pesquisa do Estado de São Paulo – FAPESP (grants n. 2014/07125-6, 2020/05207-6 for LHF and grant n. 2020/05270-0 for VDB); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES - Finance Code 001); Fundação de Amparo a Pesquisa do Estado do Amazonas - FAPEAM and from Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq). RTS is funded by NIH (R01 HL144478) and Department of Veterans Affairs (I01 BX001786).

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

REFERENCES

1. Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270–273.

2. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Heal. 2020;25(3):278–80.

3. Zhang Y-Z. Novel 2019 coronavirus genome. Shanghai Public Health Clinical Center & School of Public Health. 2020.

4. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(April):450–2.

5. Ministério da Saúde. Protocolo de Manejo Clínico para o Novo Coronavírus (2019-nCoV). 2020. p. 1 ed.

6. Dan Xu M, Fuling Zhou M, Wenbo Sun M, Liangjun Chen M, Lan Lan M, Huan Li M, et al. Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and Organ Damage in COVID-19 Patients: A Cohort Study. Clin Infect Dis. 2020;

7. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis [Internet]. 2020;50(1):54–67. Available from: https://doi.org/10.1007/s11239-020-02134-3

8. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033–40.

9. Dupont V, Kanagaratnam L, Goury A, Poitevin G, Bard M, Julien G, et al. Excess soluble fms-like tyrosine kinase 1 correlates with endothelial dysfunction and organ failure in critically ill COVID-19 patients. Clin Infect Dis. 2020;

10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.

11. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620–9.

12. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020;323(13):1239–42.

13. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission. Clin Infect Dis. 2020;71(15):896–897.

14. Henry B, de Oliveira M, Benoit S, Plebani M L. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020;58(7):1021–8.

15.   Tay MZ, Poh CM, Rénia L, MacAry PA, Ng LFP. The trinity of COVID-19:
immunity, inflammation and intervention. Nat Rev Immunol [Internet].
2020;20(6):363–74. Available from: http://dx.doi.org/10.1038/s41577-020-
0311-8

16.   Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of
immune response in patients with COVID-19 in Wuhan, China. Clin Infect
Dis. 2020;71(15):762–768.

17.   Chen L, Liu HG, Liu W, Liu J, Liu K, Shang J, et al. [Analysis of clinical
features of 29 patients with 2019 novel coronavirus pneumonia].
Zhonghua Jie He He Hu Xi Za Zhi. 2020;

18.   Han H, Ma Q, Li C, Liu R, Zhao L, Wang W, et al. Profiling serum
cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease
severity predictors. Emerg Microbes Infect. 2020;9(1):1123–30.

19.   Wang G, Wu C, Zhang Q, Wu F, Yu B, Lv J, et al. C-reactive protein level
may predict the risk of COVID-19 aggravation. Open Forum Infect Dis.
2020;7(5):1–5.

20.   Xiaomin Luo M, Wei Zhou M, Xiaojie Yan M, Tangxi Guo M, Benchao
Wang, MD Hongxia Xia M, Lu Ye M, et al. Prognostic value of C-reactive
protein in patients with COVID-19. Clin Infect Dis [Internet].
2020;23(ciaa641). Available from: 10.1093/cid/ciaa641

21.   Yao Y, Cao J, Wang Q, Shi Q, Liu K, Luo Z, et al. D-dimer as a biomarker
for disease severity and mortality in COVID-19 patients: A case control
study. J Intensive Care. 2020;8(49).

22.   Takeuchi O, Akira S. Innate immunity to virus infection. Immunol Rev.
2009;227(1):75–86.

23.   Adukpo S, Gyan BA, Ofori MF, Dodoo D, Velavan TP, Meyer CG.
Triggering receptor expressed on myeloid cells 1 (TREM-1) and cytokine
gene variants in complicated and uncomplicated malaria. Trop Med Int
Heal. 2016;21(12):1592–601.

24.   Ford JW, McVicar DW. TREM and TREM-like receptors in inflammation
and disease. Current Opinion in Immunology. 2009.

25.   Chen LC, Laskin JD, Gordon MK, Laskin DL. Regulation of TREM
expression in hepatic macrophages and endothelial cells during acute
endotoxemia. Exp Mol Pathol. 2008;

26.   Hommes TJ, Dessing MC, van 't Veer C, Florquin S, Colonna M, de Vos
AF, et al. TREM-1/3 Contribute to Protective Immunity in Klebsiella
Derived Pneumosepsis Whereas TREM-2 Does Not. Am J Respir Cell
Mol Biol. 2015;

27.   de Oliveira Matos A, Dantas P, Silva-Sales M, Sales-Campos H. The role
of the triggering receptor expressed on myeloid cells-1 (TREM-1) in non-
bacterial infections. Crit Rev Microbiol [Internet]. 2020;46(3):237–52.
Available from: https://doi.org/10.1080/1040841X.2020.1751060

28.   Dantas PH dos S, Matos A de O, da Silva Filho E, Silva-Sales M, Sales-
Campos H. Triggering receptor expressed on myeloid cells-1 (TREM-1)
as a therapeutic target in infectious and noninfectious disease: a critical
review. Int Rev Immunol [Internet]. 2020;0(0):1–15. Available from:
https://doi.org/10.1080/08830185.2020.1762597

29.   Arts R, Joosten L, van der Meer J, Netea M. TREM-1: intracellular
signaling pathways and interaction with pattern recognition receptors. J
Leukoc Biol. 2013;93(2):209–15.

30.   Weber B, Schuster S, Zysset D, Rihs S, Dickgreber N, Schürch C, et al.
TREM-1 Deficiency Can Attenuate Disease Severity without Affecting
Pathogen Clearance. PLoS Pathog. 2014;10(1):e1003900.

31.   Yuan Z, Petree JR, Lee FEH, Fan X, Salaita K, Guidot DM, et al.
Macrophages exposed to HIV viral protein disrupt lung epithelial cell
integrity and mitochondrial bioenergetics via exosomal microRNA
shuttling. Cell Death Dis. 2019;10(8):580.

32.   Tammaro A, Derive M, Gibot S, Leemans JC, Florquin S, Dessing MC.
TREM-1 and its potential ligands in non-infectious diseases: from biology
to clinical perspectives. Pharmacol Ther [Internet]. 2017;177:81–95.
Available from: http://dx.doi.org/10.1016/j.pharmthera.2017.02.043

33.   Cao C, Gu J, Zhang J. Soluble triggering receptor expressed on myeloid
cell-1 (sTREM-1): a potential biomarker for the diagnosis of infectious
diseases. Front Med. 2017;11(2):169–77.

34.   Kuemmel A, Alflen A, Schmidt LH, Sebastian M, Wiewrodt R, Schulze AB,
et al. Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung
cancer. Sci Rep. 2018;8(10766):1–9.

35.   Klesney-Tait J, Turnbull IR, Colonna M. The TREM receptor family and
signal integration. Nat Immunol. 2006;7:1266–1273.

36.   Gómez-piña V, Soares-schanoski A, Rodríguez-rojas A, Fresno C, García
F, Vallejo-cremades MT, et al. Metalloproteinases Shed TREM-1
Ectodomain from Lipopolysaccharide-stimulated Human Monocytes. J
Immunol [Internet]. 2007;179:4065–73. Available from:
http://www.jimmunol.org/content/179/6/4065.long

37.   Li Z, Zhang E, Hu Y, Liu Y, Chen B. High Serum sTREM-1 Correlates
With Myocardial Dysfunction and Predicts Prognosis in Septic Patients.
Am J Med Sci. 2016;351(6):555–62.

38.   Jedynak M, Siemiatkowski A, Mroczko B, Groblewska M, Milewski R,
Szmitkowski M. Soluble TREM-1 Serum Level can Early Predict Mortality
of Patients with Sepsis, Severe Sepsis and Septic Shock. Arch Immunol
Ther Exp (Warsz). 2018;66:299–306.

39.   Huang CT, Lee LN, Ho CC, Shu CC, Ruan SY, Tsai YJ, et al. High serum
levels of procalcitonin and soluble TREM-1 correlated with poor prognosis
in pulmonary tuberculosis. J Infect. 2014;68(5):440–7.

40.   Guideline C. Diagnosis and treatment protocol for novel coronavirus

pneumonia (Trial version 7). Chin Med J (Engl). 2020;133(9):1087–95.

41. Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol. 2020;0–1.

42. Wei T, Simko V, Levy M, Xie Y, Jin Y, Zemla J. Package 'corrplot.' Statistician. 2017;56(316):e24.

43. Harrell FE. With contributions from Charles Dupont and many others (2017)."Hmisc: Harrell Miscellaneous". R package version 4.0-1. 2020. p. 1–433.

44. Yang P, Ding Y, Xu Z, Pu R, Li P, Yan J, et al. Epidemiological and clinical features of COVID-19 patients with and without pneumonia in Beijing, China. Medrxiv. 2020;

45. Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020;395(10224):e35–e36.

46. Zheng H, Heiderscheidt CA, Joo M, Gao X, Knezevic N, Mehta D, et al. MYD88-dependent and -independent activation of TREM-1 via specific TLR ligands. Eur J Immunol. 2010;40(1):162–71.

47. Dimopoulou I, Pelekanou A, Mavrou I, Savva A, Tzanela M, Kotsaki A, et al. Early serum levels of soluble triggering receptor expressed on myeloid cells-1 in septic patients: Correlation with monocyte gene expression. J Crit Care. 2012;27(3):294–300.

48. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble Triggering Receptor Expressed on Myeloid Cells and the Diagnosis of Pneumonia. N Engl J Med. 2004;350:451–8.

49. Yuan Z, Syed M, Panchal D, Joo M, Bedi C, Lim S, et al. TREM-1-accentuated lung injury via miR-155 is inhibited by LP17 nanomedicine. Am J Physiol - Lung Cell Mol Physiol. 2016;310(5):L426-38.

50. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: A novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 2013;13(3):260–8.

51. Richard-Greenblatt M, Boillat-Blanco N, Zhong K, Mbarack Z, Samaka J, Mlaganile T, et al. Prognostic Accuracy of Soluble Triggering Receptor Expressed on Myeloid Cells (sTREM-1)-based Algorithms in Febrile Adults Presenting to Tanzanian Outpatient Clinics. Clin Infect Dis. 2020;70(7):1304–1312.

52. Liu F, Li L, Xu M Da, Wu J, Luo D, Zhu YS, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127:104370.

53. Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol. 2014;26:54–74.

54. Lai HS, Lin WH, Lai SL, Lin HY, Hsu WM, Chou CH, et al. Interleukin-6

Mediates Angiotensinogen Gene Expression during Liver Regeneration.
PLoS One. 2013;e67868.

55. McKinstry KK, Strutt TM, Buck A, Curtis JD, Dibble JP, Huston G, et al.
IL-10 Deficiency Unleashes an Influenza-Specific Th17 Response and
Enhances Survival against High-Dose Challenge. J Immunol.
2009;182(12):7353–7363.

56. Vardhana SA, Wolchok JD. The many faces of the anti-COVID immune
response. J Exp Med. 2020;217(6):e20200678.

57. The RECOVERY Collaborative G. Dexamethasone in Hospitalized
Patients with Covid-19 — Preliminary Report. N Engl J Med. 2020;